10x Genomics, Inc. income statement

In fiscal 2025, 10x Genomics, Inc. reported revenue of $643m, up 5.2% on the year before, operating income of −$61.0m (a -9.5% margin) and net income of −$43.5m, or −$0.35 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

10x Genomics, Inc.: income statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	71	146	246	299	490	516	619	611	643	617
Cost of revenue	11	29	61	58	74	120	209	196	199	185
Gross profit	61	118	185	240	416	396	409	414	444	432
Research and development	32	48	83	123	212	266	270	265	239	227
Selling, general and administrative	47	88	131	202	258	298	343	344	316	297
Operating income	−18	−111	−31	−534	−52	−168	−265	−195	−61	−88
Interest expense	1	2	3	2	1	0	0	0	0	—
Income before tax	−19	−112	−31	−534	−54	−162	−249	−178	−40	−75
Income tax	0	0	0	8	5	4	6	5	4	0
Net income	−19	−112	−31	−543	−58	−166	−255	−183	−44	−75
Diluted EPS	−$0.54	−$2.80	−$0.80	−$5.37	−$0.53	−$1.46	−$2.18	−$1.52	−$0.35	−$0.59
Diluted shares (average)	35m	40m	39m	101m	110m	114m	117m	120m	125m	128m
EBITDA	−14	−107	−24	−520	−31	−143	−230	−159	−25	−48

US$ millions unless shown otherwise. Fiscal quarters.

10x Genomics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	152	165	155	173	149	166	151	151
Cost of revenue	45	54	49	48	49	53	45	39
Gross profit	106	111	105	125	100	113	106	112
Research and development	66	67	64	61	57	56	57	57
Selling, general and administrative	82	94	90	74	75	77	66	79
Operating income	−41	−50	−39	30	−32	−20	−17	−20
Interest expense	0	0	0	0	−0	0	—	0
Income before tax	−34	−48	−34	37	−28	−15	−13	−19
Income tax	1	1	1	2	−1	1	1	−1
Net income	−36	−49	−34	35	−27	−16	−13	−18
Diluted EPS	−$0.30	−$0.41	−$0.28	$0.28	−$0.22	−$0.13	−$0.10	−$0.14
EBITDA	−33	−41	−31	38	−22	−9	−7	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AZTA vs TXG TXG vs VCYT NEO vs TXG RGEN vs TXG

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 10x Genomics, Inc.